

Salivary Status in Patients Treated for Head and Neck Cancer

(État de la salive chez les patients traités pour le cancer de la tête et du cou)

• Colin Dawes, BSc, BDS, PhD •

• Olva Odium, BDS, MSc •

S o m m a i r e

L'objectif de cette étude était de comparer le débit salivaire non stimulé et le volume salivaire résiduel (volume de salive retenu dans la bouche après la déglutition) entre un groupe de 23 sujets témoins et un groupe de 25 patients ayant reçu une radiothérapie ou subi l'exérèse des glandes salivaires (ou les 2) comme traitement pour le cancer de la tête et du cou. Comme on s'y attendait, le débit moyen (\pm écart-type) dans le groupe des patients traités était significativement moindre que dans le groupe témoin ($0,07 \pm 0,11$ et $0,45 \pm 0,27$ ml/min, respectivement). Toutefois, les volumes résiduels moyens n'étaient pas significativement différents entre les 2 groupes ($0,70 \pm 0,28$ et $0,82 \pm 0,26$ ml, respectivement). Les 25 patients traités ont été subdivisés en 3 groupes selon qu'ils avaient déclarés d'eux-mêmes aucune sécheresse buccale (3), une légère sécheresse buccale (12) et une grande sécheresse buccale (10); le volume salivaire résiduel était significativement moindre pour le groupe atteint d'une grande sécheresse buccale ($p < 0,02$), soit à 71 % du chiffre observé chez les sujets témoins. Ces résultats donnent à penser qu'il se peut que les personnes qui déclarent avoir la bouche sèche ne manquent pas complètement de salive dans la bouche, mais qu'il y ait plutôt des zones localisées de sécheresse buccale, notamment sur le palais dur, où le film salivaire est particulièrement mince et sujet à l'absorption ou à l'évaporation à cause du passage de l'air respiré dans la bouche.

Mots clés MeSH : head & neck neoplasms/radiotherapy; salivary glands/radiation effects; xerostomia/etiology

© J Can Dent Assoc 2004; 70(6):397-400
Cet article a été révisé par des pairs.

Treatment of cancer of the head and neck region can result in permanent damage to the salivary glands. When the cancer is located in the salivary tissue, the gland is usually excised. However, more patients experience damage as a result of radiation therapy to an area that encompasses salivary tissue. One or more glands may be affected by such therapy, and the possibility of recovery depends on the radiation dosage sustained by the glands.

A variety of symptoms resulting from damage to the salivary glands have been recorded, including difficulty in speaking, chewing and swallowing, increased caries rates, candidiasis and difficulties with dentures. Individual tolerance of physical damage varies greatly, and factors such as the number of glands affected are also important in determining patient outcomes.

This study was designed to assess reported symptoms and actual salivary flow rates and volumes in patients who had

been treated for head and neck cancer for comparison with an age- and sex-matched control group.

Materials and Methods

Twenty-five patients who had been treated for head and neck cancer at the Manitoba CancerCare Centre were enrolled, along with 23 control subjects who were matched as closely as possible for sex and age. The control subjects were screened to exclude anyone with medical problems that would affect saliva secretion, such as Sjögren's syndrome or medication use. The study was approved by the Health Research Ethics Board of the University of Manitoba and all participants gave informed consent. Both control subjects and patients were paid for their participation.

The participants were asked not to eat, drink or chew gum for at least 1 hour before saliva collection. At the time of sample collection, patients swallowed and then collected unstimulated whole saliva for 5 minutes (controls) or

Table 1 Demographic characteristics of control participants and patients who had been treated for head and neck cancer

Group	No. of subjects			Mean age (and range) (years)
	Total	Men	Women	
Controls	23	14	9	57.2 (41–77)
Patients	25	16	9	57.4 (42–75)

10 minutes (patients) by drooling into a funnel placed in a graduated centrifuge tube. At the end of the collection period each participant spat into the funnel any saliva remaining in the mouth. The volume was recorded and the flow rate calculated. After an interval of at least 5 minutes, during which normal swallowing was permitted, the participants swallowed and then rinsed the mouth for about 5 seconds with about 5 mL of distilled water taken from a paper cup and then expectorated into a different paper cup. The paper cup that had contained the distilled water was weighed before and after the water was taken into the mouth to determine the precise volume used (V). The unstimulated saliva and the expectorate were assayed for potassium concentration (C_s and C_e , respectively) by atomic absorption spectroscopy,¹ and the residual volume of saliva (RV) was calculated as $RV = (V \times C_e) / (C_s - C_e)$, as described previously.¹

The patient group also completed a questionnaire regarding the cause and duration of salivary damage and any symptoms they were experiencing. Patient records were checked to determine the treatment previously provided and the salivary glands that might have been affected by the treatment.

Results

The control participants and the patients were similar in age and sex ratio (Table 1). The questionnaire data allowed a breakdown of the patient group into 3 categories of xerostomia (Table 2): mouth not perceived as dry (3 patients), mouth perceived as somewhat dry (12) and mouth perceived as very dry (10). On a scale of 0 to 10, where 0 = very good appetite and 10 = no appetite, most patients (15) claimed to have a very good appetite (mean score 2.0). On a scale of 0 to 10, where 0 = no difficulty in swallowing and 10 = great difficulty in swallowing, only 6 patients reported no difficulty in swallowing. The mean swallowing scores for the patients whose mouths felt not dry, somewhat dry or very dry were 0.6, 2.3 and 4.5, respectively. No subjects in the control group reported a poor appetite or a dry mouth.

Of the 3 patients who reported no oral dryness, 2 had lost 1 gland only to surgery, whereas the other patient had had 2 glands exposed to radiation and may have experienced some recovery of the tissue. Of the 12 patients with a somewhat dry mouth, 5 had lost 1 gland and 6 had lost 2 glands; for the other patient, 4 glands had been in the radiation field. Of the

Table 2 Treatments, salivary glands affected by treatment and self-reported degree of mouth dryness among 25 patients who had been treated for head and neck cancer

	No. of patients
Treatment	
Gland removal only	2
Radiation only	12
Radiation plus gland removal	11
Salivary glands affected	
1 parotid	2
1 submandibular	5
1 parotid and 1 submandibular	3
2 submandibular	9
2 parotid and 2 submandibular	6
Self-reported dryness of mouth	
Not dry	3
Somewhat dry	12
Very dry	10

10 patients with a very dry mouth, 8 had been treated with external radiation as the primary management modality. The 2 other patients had wide surgical fields with subsequent high-dose radiation, including the area of 2 major salivary glands.

The flow rates of unstimulated whole saliva, residual saliva volumes and salivary potassium concentrations are presented in Table 3. The mean salivary potassium concentrations (\pm SD) in the 3 groups of patients who reported that their mouths were not dry, somewhat dry or very dry were 29.4 ± 8.2 , 29.5 ± 10.7 and 23.9 ± 9.3 mmol/L, respectively. One-way analysis of variance showed no significant differences ($p > 0.05$) in potassium concentrations between the control subjects and the 3 patient subgroups. The method for estimating residual volume used the potassium concentration of each person's saliva. Although this method has not been validated for patients who have undergone therapy for head and neck cancer, there is no reason to believe that it would not be applicable to the patient groups in this study, given that the mean salivary potassium concentrations in these groups were not significantly different from that of the control group (Table 3).

The individual and mean unstimulated flow rates and residual saliva volumes for the control subjects and the 3 groups of patients are shown in Figs. 1 and 2, respectively. Analysis of variance and a Duncan new multiple-range test revealed significantly lower flow rates in the patient groups than the control group (Fig. 1; $p < 0.001$), but the differences among the 3 patient groups were not statistically significant ($p > 0.05$). When the residual volumes of the 3 patients who did not have a dry mouth were pooled with those for the control subjects, analysis of variance revealed significant differences between the controls and the other 2 patient groups. A Duncan new multiple-range test showed that the

Table 3 Unstimulated salivary flow rates, residual salivary volumes and salivary potassium concentrations for control participants and patients who had been treated for head and neck cancer^a

Group	No. of participants	Flow rate (mL/min)	Residual volume (mL)	K concentration (mmol/L)
Controls	23	0.45 ± 0.27	0.82 ± 0.26	23.9 ± 5.9
Patients	25	0.07 ± 0.11	0.70 ± 0.28	27.3 ± 9.9

^aData are presented as mean ± standard deviation.




Figure 1: Unstimulated salivary flow rates in control subjects and in 3 subgroups of patients. The horizontal lines indicate the mean values.

mean residual volume for patients whose mouths felt somewhat dry was not significantly different from that for the control group or the patients whose mouths felt very dry. However, the mean residual volumes of the latter 2 groups were significantly different from each other, and the mean residual volume for patients who stated that their mouth felt very dry was only 71% of that for the control group (Fig. 2; $p < 0.02$).

Discussion

Xerostomia is the subjective sensation of dry mouth and should be distinguished from hyposalivation, the objective measurement of a low salivary flow rate.² The normal unstimulated salivary flow rate averages just over 0.3 mL/min, and a flow rate of < 0.1 mL/min is usually considered evidence of hyposalivation.³

A certain volume of saliva, termed the residual volume, is left in the mouth after swallowing; this has been reported to average 0.77 mL (range 0.38–1.73 mL) in healthy people with no salivary gland disorders.¹ The volume of saliva in the mouth is increased by in-flow of fresh saliva until swallowing is again induced, by which time the volume averages 1.07 mL (range 0.52–2.14 mL).¹ Thus, in healthy individuals, the volume of saliva in the mouth when food or drink is not being consumed fluctuates between about 0.77 and about 1.07 mL.

As well as by swallowing, salivary fluid can be lost by evaporation and by absorption through the oral mucosa.⁴ In the absence of these 2 processes, individuals with even a very low salivary flow rate would not be expected to experience




Figure 2: Residual salivary volume in control subjects and in 3 subgroups of patients. The horizontal lines indicate the mean values.

xerostomia. The residual volume would be the same and they would simply swallow less frequently, because with a low salivary flow rate it would take longer to reach the volume at which swallowing is triggered. However, if evaporation and mucosal fluid absorption are clinically significant factors in removal of saliva from the mouth, then people with xerostomia might be expected to have lower-than-normal residual volumes.

In this study, the very low unstimulated salivary flow rates in most of the patients (Fig. 1) were not unexpected, particularly for those who had received wide-field radiation treatment. The mean residual volume in the control subjects (0.82 mL) was very similar to the value of 0.77 mL reported previously.¹ It was only in the patients who stated that their mouths felt very dry that the mean residual salivary volume was significantly less, by 29%, than that in the control group (Fig. 2). In fact no patient had a residual volume less than 50% of the mean value in the control subjects.

The residual volume of saliva is normally present in the mouth as a thin film, averaging about 72 μ m in thickness and separating the oral surfaces that would otherwise be in direct contact with each other.⁵ Estimation of the mean film thickness in a particular individual necessitates knowledge of the residual volume and the surface area of the mouth, and the latter was not available in this study. However, with a mean reduction of 29% in the residual volume for patients whose mouth felt very dry, a significant reduction in thickness of the salivary film would certainly be expected. When individual oral surfaces such as the tongue and palate are separated from

each other, the mean retained film thickness after swallowing will average about 36 μm , half the total film thickness. However, DiSabato-Mordarski and Kleinberg⁶ found marked site-specific variation in the thickness of the surface fluid layer, with mean values ranging from 70 μm on the posterior dorsum of the tongue to 10 μm on the hard palate. In addition, Wolff and Kleinberg⁷ reported that in patients with dry mouth and unstimulated flow rates of less than 0.1 mL/min, the mean mucosal salivary film thickness was only 22.4 μm , the site specificity of the film thickness was maintained, and salivary films of < 10 μm on the hard palate were associated with complaints of dry mouth.

These previous studies, as well as the current data on residual salivary volume in xerostomic patients, suggest that people who report dryness of the mouth do not have a complete lack of fluid in their mouth but rather a reduced residual volume, which probably creates localized areas of dryness, especially on the hard palate, where dryness is readily perceived. A salivary film of less than 10 μm thickness on the hard palate would be particularly susceptible to evaporation if there is any mouth breathing. As discussed elsewhere in more detail,⁴ saliva evaporation and mucosal fluid absorption appear to be important factors in the development of xerostomia. The findings of this study suggest that more severe symptoms (e.g., feelings of dryness and difficulty in eating, leading in turn to loss of appetite) occur when all 4 major salivary glands have been damaged. This situation is most likely to arise after external-beam wide-field radiation treatment.

For patients who have undergone hemifacial treatment, symptoms are less severe, and improvement over time suggests that adaptation occurs. Nevertheless, all patients who have undergone treatment for head and neck cancer require close dental monitoring in the early recovery stage, and patients with very dry mouth can be expected to encounter lifelong dental problems.

Pilocarpine, which stimulates salivary flow, is effective in relieving dry mouth in some patients. However, several clinical trials^{8,9} have shown that pilocarpine has undesirable side effects, such as increased sweating, and may be contraindicated in persons with asthma or glaucoma. Nonpharmacologic ways for patients with dry mouth to alleviate the severity of symptoms include drinking plenty of water to maintain the maximum unstimulated salivary flow rate; avoiding mouth breathing to reduce evaporation of saliva; using a humidifier in the winter to increase the relative humidity, especially in the bedroom, as mouth breathing commonly occurs during sleep; avoiding tobacco, caffeine and alcohol, which have a drying or diuretic effect; chewing sugar-free gum or candy to stimulate salivary flow; and using water or saliva substitutes. It is recommended that patients with dry mouth use specially formulated dentifrice to help prevent dental caries. ♦



Le Dr Dawes est professeur de biologie buccale, Faculté de médecine dentaire, Université du Manitoba, Winnipeg (Manitoba).



La Dre Odlum est chercheuse principale, Faculté de médecine dentaire, Université du Manitoba, et dentiste-conseil chez CancerCare Manitoba, Winnipeg.

Écrire au : Dr C. Dawes, Département de biologie buccodentaire, Faculté de médecine dentaire, Université du Manitoba, 780, av. Bannatyne, Winnipeg MB R3E 0W2. Courriel : Colin_Dawes@umanitoba.ca.

Les auteurs n'ont aucun intérêt financier déclaré.

Références

1. Lagerlof F, Dawes C. The volume of saliva in the mouth before and after swallowing. *J Dent Res* 1984; 63(5):618–21.
2. Nederfors T. Xerostomia and hyposalivation. *Adv Dent Res* 2000; 14:48–56.
3. Saliva: its role in health and disease. Working Group 10 of the Commission on Oral Health and Epidemiology (CORE). *Int Dent J* 1992; 42(Suppl 2):287–304.
4. Dawes C. How much saliva is enough for avoidance of xerostomia? *Caries Res* 2004; 38(3):236–40.
5. Collins LM, Dawes C. The surface area of the adult human mouth and thickness of the salivary film covering the teeth and oral mucosa. *J Dent Res* 1987; 66(8):1300–2.
6. DiSabato-Mordarski T, Kleinberg I. Measurement and comparison of the residual saliva on various oral mucosal and dentition surfaces in humans. *Arch Oral Biol* 1996; 41(7):655–65.
7. Wolff M, Kleinberg I. Oral mucosal wetness in hypo- and normosalivators. *Arch Oral Biol* 1998; 43(6):455–62.
8. Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, and others. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. *N Engl J Med* 1993; 329(6):390–5.
9. Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL 3rd, Tran-Johnson TK, and others. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. *Arch Intern Med* 1999; 159(2):174–81.

Remerciements : Nous remercions les participants pour leur contribution à cette étude, Mme B. Grimshire pour son excellente aide technique et Mme Mary Cheang, de l'Unité de consultation biostatistique de l'Université du Manitoba, pour ses analyses statistiques.